Human IFN-γ Antibody - Fontolizumab Biosimilar

Human IgG1 - CAS #326859-36-3

ABOUT

Anti-human IFN gamma - Fontolizumab biosimilar - CAS #326859-36-3

Anti-hIFN-γ-hIgG1 is a biosimilar antibody of Fontolizumab, a therapeutic antibody that targets interferon gamma (IFN-γ). This monoclonal antibody (mAb) blocks the interaction of IFN-γ with its receptor. Fontolizumab has been clinically tested as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis.

More details More details

 

Anti-hIFN-γ-hIgG1 comprises the variable region of Fontolizumab and the IgG1 constant region of Fontolizuma with high effector functions.

This antibody can be used with& HEK-Blue™ IFN-γ cells for screening and neutralization assays to block recombinant human IFN-γ-induced signaling (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined using the EndotoxDetect™ assay.

All products are for internal research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

Human IFN-γ

Target species

Human

Species
Human
Isotype
hIgG1
kappa
Clone
Fontolizumab
CAS number
326859-36-3
Synonyms
HuZAF™
Molecular weight
148 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIFN-γ-hIgG1
  • Cat code: 
    hifng-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Fontolizumab background

Fontolizumab (aka HuZAF™) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-gamma (IFN-γ) cytokine [1, 2]. By binding to IFN-γ, Fontolizumab prevents it from interacting with its receptor (IFN-γR) on the surface of immune cells, thus inhibiting downstream inflammatory response. Fontolizumab was used as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis. While the mode of action was promising, clinical trials did not demonstrate sufficient clinical benefit [3, 4].

 

References:

1. Hommes D.W., et al., 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 55(8):1131-1137.
2. Reinisch W et al., 2006. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut, 55(8):1138-1144.
3. Reinisch W et al., 2009. Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Infl Bowel Dis., 16(2):233-242.
4. Harden J.L., et al., 2015. Humanized anti-IFNg (HuZAF) in the treatment of psoriasis. J. Aller Clin Immunol. 135(2):553.

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?